Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome

Journal of Oncology Pharmacy Practice

Volumn 16, Issue 3, 2010, Pages 205-213

  Kennedy, Leanne D ^a   Ajiboye, Violette O ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

hematologic malignancy; hyperuricemia; rasburicase; tumor lysis syndrome

Indexed keywords

ADENINE; ALLOPURINOL; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BICARBONATE; CALCIUM PHOSPHATE; CREATININE; CYTOTOXIC AGENT; CYTOTOXIC ANTIBODY; DIURETIC AGENT; FEBUXOSTAT; GUANINE; HYPOXANTHINE; LACTATE DEHYDROGENASE; MERCAPTOPURINE; PHOSPHATE; RASBURICASE; URIC ACID; URICOZYME; XANTHINE; XANTHINE OXIDASE INHIBITOR;

ACIDURIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALKALINIZATION; ANAPHYLAXIS; ANOREXIA; BACKACHE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE PREDISPOSITION; DIURESIS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; FLANK PAIN; FLUID THERAPY; GASTROINTESTINAL SYMPTOM; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GOUT; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HEMATURIA; HEMODIALYSIS; HEMOLYSIS; HEMOLYTIC ANEMIA; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYDRATION; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOVOLEMIA; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LENGTH OF STAY; LETHARGY; LEUKOCYTE COUNT; LYMPHOBLASTOMA; METABOLIC ALKALOSIS; METHEMOGLOBINEMIA; MICTURITION; MUSCLE CRAMP; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; OBSTRUCTIVE UROPATHY; OLIGURIA; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEIZURE; SEPSIS; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SOLID TUMOR; TETANY; TUMOR LYSIS SYNDROME; UREMIA; URIC ACID BLOOD LEVEL; URINARY EXCRETION; URINE FLOW RATE; VOMITING;

ALLOPURINOL; ANTINEOPLASTIC AGENTS; GOUT SUPPRESSANTS; HEMATOLOGIC NEOPLASMS; HUMANS; HYPERURICEMIA; INFUSIONS, INTRAVENOUS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 77956259012     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155209348719     Document Type: Review

References (31)

1. Coiffier B., Altman A., Pui CH, Younes A., Cairo MS Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008 ; 26: 2767-2778.
2. Hochberg J., Cairo MS Tumor lysis syndrome: current perspective. Haematologica 2008 ; 93: 9-13.
3. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004 ; 127: 3-11.
4. Hande KR, Garrow GC Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993 ; 94: 133-139.
5. Oda M., Satta Y., Takenaka O., Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002 ; 19: 640-653.
6. Rampello E., Fricia T., Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006 ; 3: 438-447.
7. DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966 ; 274: 481-486.
8. Krakoff IH, Meyer RL Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. JAMA 1965 ; 193: 1-6.
9. Smalley RV, Guaspari A., Haase-Statz S., Anderson SA, Cederberg D., Hohneker JA Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 2000 ; 18: 1758-1763.
10. Aloprim (allopurinol sodium) for injection (package insert). Boca Raton, FL: Nabi, 2003.
11. Allopurinol (prescribing information). Corona, CA: Watson Laboratories, Inc., 2006.
12. Becker MA, Schumacher Jr HR, Wortmann RL, MacDonald PA, Eustace D., Palo WA et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005 ; 353: 2450-2461.
13. Elitek (prescribing information). Bridgewater, NJ: sanofi-aventis US, 2008.
14. Data on File. Bridgewater, NJ: sanofi-aventis US, 2009.
15. Fasturtec (summary of product characteristics). London, UK: European Medicines Agency, 2008.
16. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R., Kreissman S., Johnson FL et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001 ; 97: 2998-3003.
17. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G., Camitta B. et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001 ; 19: 697-704.
18. Coiffier B., Mounier N., Bologna S., Ferme C., Tilly H., Sonet A. et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003 ; 21: 4402-4406.
19. Jeha S., Kantarjian H., Irwin D., Shen V., Shenoy S., Blaney S. et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005 ; 19: 34-38.
20. Liu CY, Sims-McCallum RP, Schiffer CA A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 2005 ; 29: 463-465.
21. Ho VQ, Wetzstein GA, Patterson SG, Bradbury R. Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome. Support Cancer Ther 2006 ; 3: 178-182.
22. Hunter HM, Rule SAJ Rasburicase is effective in the prophylaxis of tumour lysis syndrome when used over a short duration in patients with haematological malignancy. Br J Haematol 2005 ; 129 (suppl 1). 42.
23. Wang LY, Shih LY, Chang H., Jou ST, Lin KH, Yeh TC et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol 2006 ; 115: 35-38.
24. Arnold TM, Reuter JP, Delman BS, Shanholtz CB Use of single-dose rasburicase in an obese female. Ann Pharmacother 2004 ; 38: 1428-1431.
25. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J., Hall PD Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006 ; 26: 806-812.
26. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006 ; 26: 242-247.
27. Reeves DJ, Bestul DJ Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 2008 ; 28: 685-690.
28. Trifilio S., Gordon L., Singhal S., Tallman M., Evens A., Rashid K. et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transpl 2006 ; 37: 997-1001.
29. Lee AC, Li CH, So KT, Chan R. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003 ; 37: 1614-1617.
30. Centers for Medicare & Medicaid Services, 2009. Average Sales Price Drug Pricing Files. Available at: http://www.cms.hhs.gov/apps/ama/license.asp? file=/McrPartBDrugAvgSalesPrice/downloads/April-2009-ASP-Pricing-File-by-HCPCS. zip. (accessed March 23, 2009 ).
31. Bell T., Candrilli S., Irish W., Morris E., Goldman SC, Cairo MS Acute renal failure (ARF) with or without dialysis (D) is associated with a significant increase in mean length of stay (LOS) and total costs (TC) in patients hospitalized with acute leukemia (AL) and/or lymphoma (L). Proc Am Soc Clin Oncol 2003 ; 22 (abstr 2195 ).